In a report issued on January 2, Mark Massaro from Canaccord Genuity reiterated a Buy rating on Natera (NTRA), with a price target of $27. The company’s shares closed on Friday at $12.68.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 12.0% and a 53.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.
Natera has an analyst consensus of Strong Buy, with a price target consensus of $27.33.
See today’s analyst top recommended stocks >>
Based on Natera’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $29.62 million. In comparison, last year the company had a GAAP net loss of $45.5 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception, and Non-Invasive Paternity Testing.
